Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents.
Papa A, Cursaro I, Pozzetti L, Contri C, Cappello M, Pasquini S, Carullo G, Ramunno A, Gemma S, Varani K, Butini S, Campiani G, Vincenzi F.
Papa A, et al. Among authors: pasquini s.
Arch Pharm (Weinheim). 2023 Dec;356(12):e2300410. doi: 10.1002/ardp.202300410. Epub 2023 Sep 26.
Arch Pharm (Weinheim). 2023.
PMID: 37750286